Lantheus Holdings (LNTH) said Monday it has agreed to acquire Life Healthcare Group subsidiary Life Molecular Imaging in an all-cash deal worth up to $750 million.
The consideration consists of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments. Lantheus Radiopharmaceuticals UK, a unit of Lantheus, may pay up to $30 million toward Life Medical Group's retained future contingent liabilities, subject to certain contract arrangements.
The deal is expected to complete in H2 2025, subject to clearance from regulators and approval from Life Healthcare's shareholders.
Lantheus expects the deal to be accretive to adjusted per-share earnings within 12 months of completion.
The company anticipates that the acquisition will strengthen its growth profile with the addition of Neuraceq, a diagnostic agent to detect beta-amyloid plaques in patients with Alzheimer's Disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.